Ovarian Cancer: Advances in HER2-Targeted ADCs

Targeting HER2 Across Advanced Solid Tumors

Ovarian Cancer: Advances in HER2-Targeted ADCs

ReachMD Healthcare Image
Media formats available:
  • Overview

    HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents. 

    On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Susana Banerjee, MBBS, MA, FRCP, PhD 
    Consultant Medical Oncologist 
    Research Lead Gynaecology Unit 
    The Royal Marsden NHS Foundation Trust 
    Professor in Women’s Cancers 

    Dr. Banerjee has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: AstraZeneca, GlaxoSmithKline Immunogen, Merck Sharpe Dohme, Mersana, Myriad, Oncxerna, Seagen, Takeda, Verastem  
    Contracted Research: AstraZeneca,GlaxoSmithKline, Verastem, Immunogen, MSD, Mersana, Seagen 
    Ownership Interest: Phenutest  

    Bradley McGregor, MD 
    Director, Clinical Research for the Lank Center of Genitourinary Oncology 
    Dana-Farber Cancer Institute 
    Boston, MA 

    Dr. McGregor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: BMS, Eisai, Exelixis, Gilead, Pfizer, Seagen
    Contracted Research: BMS, Exelixis, Gilead, Pfizer, Seagen

    Kathleen N. Moore, MD, MS 
    Co-Director, Cancer Therapeutics Program 
    Stephenson Cancer Center at the University of Oklahoma HSC 
    Oklahoma City, OK  

    Dr. Moore has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Aadi, Aravive, Astra Zeneca, Blueprint, Clovis, Caris, Duality, Eisai, Genentech/Roche, GSK, Immunogen, Janssen, Lilly, Merck, Mersana, Onconova, Pannavance, Regeneron, VBL, Verastem, ZEntalis
    Contracted Research: Aravie, Astra Zeneca, Blueprint, Clovis, Duality, GSK, Genentech/Roche, Immunogen, Lilly, PTC Therapeutics, Regeneron, Verastem

    Shubham Pant, MD, MBBS 
    Associate Professor 
    Department of Gastrointestinal Medical Oncology 
    Division of Cancer Medicine 
    The University of Texas MD Anderson Cancer Center 
    Houston, TX 

    Dr. Pant has reported no relevant disclosures at this time.

    Reviewers/Content Planners/Authors: 

    • Jorge Bacigalupo, PSM, has nothing to disclose. 
    • Cindy Davidson has nothing to disclose.  
    • Ann Early has nothing to disclose. 
    • Amanda Hilferty has nothing to disclose. 
    • Stephanie Wenick has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:  

    • Evaluate the unmet need and rationale for exploring HER2 antibody-drug conjugates (ADCs) in advanced solid tumors.  
    • Analyze clinical trial evidence from ASCO and ESMO 2023 on HER2-directed ADCs in advanced solid tumors in the context of treatment sequencing.  
    • Identify the role of liquid biopsy in detecting HER2 alterations at baseline, during therapy, and/or at disease progression in advanced solid tumors. 
  • Target Audience

    This activity is designed to meet the educational needs of gynecologic oncologists, medical oncologists, community and academic practice ob-gyns, and GU specialists, urologists, and the advanced practice professionals associated with these specialties. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.  

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.   

  • Commercial Support

    This activity is supported by an independent educational grant from AstraZeneca and Daiichi Sankyo, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free